WHAT IS CLAIMED IS:

1. A compound of Formula (I) or a pharmaceutically acceptable salt thereof:



(I)

wherein

R^1 is $(CH_2)_nR^2$, wherein n is 1, 2, or 3, and R^2 is cyclohexyl, phenyl, thiophen-2-yl, thiophen-3-yl, pyridine-2-yl, adamantyl, 2,3-dihydro-1H-inden-2-yl, 1,2,3,4-tetrahydronaphthalen-2-yl, spiro[2.5]octan-6-yl, spiro[3.5]nonan-7-yl, spiro[4.5]decan-8-yl, (5S,8s)-3,3-dimethyl-2-oxaspiro[4.5]decan-8-yl, (benzo[d][1,3]dioxol-5-yl)methyl, (2,3-dihydrobenzo[b][1,4]dioxin-6-yl)methyl, 1-cyclohexylazetidin-3-yl,

 ,  , or  each optionally substituted from one up to the maximum number of substituents with one or more of F, Cl, C_{1-6} alkyl, C_{2-6} alkenyl, cyclopropyl, difluoromethyl, 1,1-difluoroethyl-1-yl, 2-fluoropropan-2-yl, methoxymethyl, OCF_3, CF_3, phenyl, pyrrolidin-1-yl, piperidin-1-yl, 4-morpholino, C_{1-6} alkoxy, cyclopropylmethoxy, (tetrahydrofuran-3-yl)oxy, (tetrahydro-2H-pyran-3-yl)oxy, (tetrahydro-2H-pyran-4-yl)oxy, phenoxy, (tetrahydrofuran-3-yl)methoxy, tetrahydro-2H-pyran-4-yl, 3,5-dimethylisoxazol-4-yl, and/or 3,5-dimethyl-1H-pyrazol-4-yl;

where R^3 is C_{1-6} alkyl, phenyl, pyridine-2-yl, pyridin-3-yl, benzo[d]thiazol-2-yl, cyclohexylcarbamothioyl, or cyclohexylcarbamoyl, each optionally substituted from one up to the maximum number of substituents with one or more of F, Cl, C_{1-6} alkyl, C_{2-6} alkenyl, cyclopropyl, C_{1-6} alkoxy, OCF_3, and/or CF_3; and

where R^4 is C_{1-6} alkyl, C_{3-7} cycloalkyl, phenyl, thiophen-3-yl, phenylmethyl, or cyclopentylmethyl, each optionally substituted from one up to the maximum number of substituents with one or more of F, C_{1-6} alkyl, OCH_3, and/or CF_3; and

where m is 1 or 2; and

where R^5 is phenyl, pyridin-2-yl, pyridin-3-yl, pyridin-4-yl, pyrimidin-5-yl, thiophen-3-yl, benzo[d]thiazol-4-yl, benzo[d]thiazol-2-yl, phenylcarbonyl, thiazol-2-yl, benzo[d]oxazol-2-yl, or benzo[d]thiazol-2-yl, each optionally substituted from one up to the maximum number of substituents with one or more of F, Cl, C_{1-6} alkyl, C_{1-6} alkoxyl, OCF_3, and/or CF_3,

with the proviso that R^1 is not benzyl or 3-phenylpropyl.

2. The compound of claim 1 wherein:

R^1 is $(CH_2)_nR^2$, wherein n is 1 or 2, and R^2 is cyclohexyl, cyclohexylmethyl, phenylethyl, 4-phenylcyclohexyl, 4-(trifluoromethoxy)cyclohexyl, spiro[2.5]octan-6-yl, spiro[3.5]nonan-7-yl, spiro[4.5]decan-8-yl, (5S,8s)-3,3-dimethyl-2-oxaspiro[4.5]decan-8-yl, 1,2,3,4-tetrahydronaphthalen-2-yl, 2,3-dihydro-1H-inden-2-yl, (adamantyl)methyl, (pyridine-2-yl)methyl, (benzo[d][1,3]dioxol-5-yl)methyl, (2,3-dihydrobenzo[b][1,4]dioxin-6-yl)methyl, ([1,1'-biphenyl]-4-yl)methyl, 1-(2,2,2-trifluoroethyl)piperidin-4-yl, 1-(pyridin-3-yl)piperidin-4-yl, 1-(pyridin-2-yl)piperidin-4-yl, 1-(benzo[d]thiazol-2-yl)piperidin-4-yl, 1-(cyclohexylcarbamoyl)piperidin-4-yl, 1-(cyclohexylcarbamothioyl)piperidin-4-yl, 1-phenylpiperidin-4-yl, 1-cyclohexylazetidin-3-yl, thiophen-2-yl, 2-(thiophen-2-yl)methyl, or 2-(thiophen-3-yl)methyl, each optionally substituted from one up to the maximum number of substituents with one or more of F, Cl, C_{1-6} alkyl, cyclopropyl, vinyl, difluoromethyl, 1,1-difluoroethyl-1-yl, 2-fluoropropan-2-yl, methoxymethyl, C_{1-6} alkoxy, and/or CF_3; or

R^1 is benzyl, substituted from one up to the maximum number of substituents with one or more of F, Cl, C_{1-6} alkyl, phenyl, pyrrolidin-1-yl, piperidin-1-yl, C_{1-6} alkoxy, cyclopropylmethoxy, phenoxy, and/or CF_3; or

R^1 is phenylethyl, optionally substituted from one up to the maximum number of substituents with one or more of pyrrolidin-1-yl, piperidin-1-yl, 4-morpholino, cyclopropylmethoxy, (tetrahydrofuran-3-yl)oxy, (tetrahydro-2H-pyran-3-yl)oxy, (tetrahydro-2H-pyran-4-yl)oxy, phenoxy, (tetrahydrofuran-3-yl)methoxy, tetrahydro-2H-pyran-4-yl, 3,5-dimethylisoxazol-4-yl, 3,5-dimethyl-1H-pyrazol-4-yl, F, Cl, C_{1-6} alkyl, cyclopropyl, propen-2-yl, OCH_3, and/or CF_3; or

R^1 is (1-formylpiperidin-4-yl)methyl, substituted on the formyl group with one of: C_{1-6} alkyl, C_{3-7} cycloalkyl, phenyl, thiophen-3-yl, phenylmethyl, or cyclopentylmethyl, each optionally substituted from one up to the maximum number of substituents with one or more of F, C_{1-6} alkyl, OCH_3, and/or CF_3; or

R^1 is  ,  ,  , or  , where R^6 is selected from the group consisting of: phenyl, pyridin-2-yl, pyridin-3-yl, pyridin-4-yl, pyrimidin-5-yl, thiophen-3-yl, benzo[d]thiazol-4-yl, benzo[d]thiazol-2-yl, phenylcarbonyl, thiazol-2-yl, benzo[d]oxazol-2-yl, and benzo[d]thiazol-2-yl, each optionally substituted from one up to the maximum number of substituents with one or more of F, Cl, C_{1-6} alkyl, C_{1-6} alkoxyl, OCF_3, and/or CF_3,

with the proviso that R^1 is not benzyl or 3-phenylpropyl.

3. The compound of claim 1 wherein:

R^1 is cyclohexylmethyl, (4,4-dimethylcyclohexyl)methyl, (4,4-difluorocyclohexyl)methyl, (4,4-dichlorocyclohexyl)methyl, (4-ethylcyclohexyl)methyl, ((1s,4S)-4-vinylcyclohexyl)methyl, ((1s,4S)-4-isopropylcyclohexyl)methyl, ((1r,4R)-4-isopropylcyclohexyl)methyl, 4-(tert-butyl)cyclohexyl)methyl, ((1s,4S)-4-(tert-butyl)cyclohexyl)methyl, ((1r,4R)-4-(tert-butyl)cyclohexyl)methyl, ((1s,4S)-4-(trifluoromethyl)cyclohexyl)methyl, ((1r,4R)-4-(trifluoromethyl)cyclohexyl)methyl, ((1s,4S)-4-(2-fluoropropan-2-yl)cyclohexyl)methyl, ((1r,4R)-4-(2-fluoropropan-2-yl)cyclohexyl)methyl, ((1s,4S)-4-methoxycyclohexyl)methyl, ((1r,4R)-4-methoxycyclohexyl)methyl, (4-(methoxymethyl)cyclohexyl)methyl, ((1s,4S)-4-cyclopropylcyclohexyl)methyl, ((1r,4R)-4-cyclopropylcyclohexyl)methyl, (4-phenylcyclohexyl)methyl, (spiro[2.5]octan-6-yl)methyl, (spiro[3.5]nonan-7-yl)methyl, (spiro[4.5]decan-8-yl)methyl, 2-cyclohexylethyl, 2-(4,4-difluorocyclohexyl)ethyl, 2-((1s,4S)-4-(trifluoromethyl)cyclohexyl)ethyl, 2-((1r,4R)-4-(trifluoromethyl)cyclohexyl)ethyl, 2-(adamantan-1-yl)ethyl, 3-cyclohexylpropyl, phenethyl, 2-methylphenethyl, 2-methoxyphenethyl, 2-fluorophenethyl, 2-chlorophenethyl, 2,3-difluorophenethyl, 2,4-difluorophenethyl, 2,5-difluorophenethyl, 3,4-difluorophenethyl, 2-fluoro-4-methoxyphenethyl, 3-chloro-2-fluorophenethyl, 4-chloro-2-fluorophenethyl, 5-chloro-2-fluorophenethyl, 2,6-difluorophenethyl, 3-chloro-2,6-difluorophenethyl, 2,6-difluoro-4-(prop-1-

en-2-yl)phenethyl, 2,6-difluoro-4-isopropylphenethyl, 2,6-difluoro-3-isopropylphenethyl, 4-cyclopropyl-2,6-difluorophenethyl, 2,6-difluoro-4-(trifluoromethyl)phenethyl, 2,6-difluoro-4-(pyrrolidin-1-yl)phenethyl, 2,6-difluoro-4-(piperidin-1-yl)phenethyl, 2,6-difluoro-4-morpholinophenethyl, 4-butoxy-2,6-difluorophenethyl, 4-(cyclopropylmethoxy)-2,6-difluorophenethyl, 4-((tetrahydrofuran-3-yl)oxy)phenethyl, 4-((tetrahydro-2H-pyran-3-yl)oxy)phenethyl, 4-((tetrahydro-2H-pyran-4-yl)oxy)phenethyl, 4-phenoxyphenethyl, 4-((tetrahydrofuran-3-yl)methoxy)phenethyl, (R)-2-phenylpropyl, (S)-2-phenylpropyl, 2-([1,1'-biphenyl]-4-yl)ethyl, 2-(3,5-difluoro-[1,1'-biphenyl]-4-yl)ethyl, 2-(benzo[d][1,3]dioxol-5-yl)ethyl, 2-(6-fluorobenzo[d][1,3]dioxol-5-yl)ethyl, 2-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)ethyl, 2-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)ethyl, 2-(thiophen-2-yl)ethyl, 2-(thiophen-3-yl)ethyl, 2-(pyridine-2-yl)ethyl, 3-(2-fluorophenyl)propyl, 3-(4-fluorophenyl)propyl, 3-(thiophen-2-yl)propyl, 3-(thiophen-3-yl)propyl, (1-phenylpiperidin-4-yl)methyl, (1-(2-fluorophenyl)piperidin-4-yl)methyl, (1-(3-fluorophenyl)piperidin-4-yl)methyl, (1-(4-fluorophenyl)piperidin-4-yl)methyl, (1-(4-(trifluoromethyl)phenyl)piperidin-4-yl)methyl, (4-methyl-1-phenylpiperidin-4-yl)methyl, (4-fluoro-1-phenylpiperidin-4-yl)methyl, 2-(1-phenylpiperidin-4-yl)ethyl, (1-(2,2,2-trifluoroethyl)piperidin-4-yl)methyl, (1-isobutyrylpiperidin-4-yl)methyl, (1-pivaloylpiperidin-4-yl)methyl, (1-butyrylpiperidin-4-yl)methyl, (1-(3-methylbutanoyl)piperidin-4-yl)methyl, (1-(3,3-dimethylbutanoyl)piperidin-4-yl)methyl, (1-(2-cyclopentylacetyl)piperidin-4-yl)methyl, (1-(cyclopropanecarbonyl)piperidin-4-yl)methyl, (1-(cyclobutanecarbonyl)piperidin-4-yl)methyl, (1-(cyclopentanecarbonyl)piperidin-4-yl)methyl, (1-(cyclohexanecarbonyl)piperidin-4-yl)methyl, (1-((1s,4s)-4-(tert-butyl)cyclohexanecarbonyl)piperidin-4-yl)methyl, (1-((1r,4r)-4-(tert-butyl)cyclohexanecarbonyl)piperidin-4-yl)methyl, (1-(4-methoxycyclohexanecarbonyl)piperidin-4-yl)methyl, (1-(4-(trifluoromethyl)cyclohexanecarbonyl)piperidin-4-yl)methyl, (1-benzoylpiperidin-4-yl)methyl, (1-(3-(trifluoromethyl)benzoyl)piperidin-4-yl)methyl, (1-(2-phenylacetyl)piperidin-4-yl)methyl, (1-(thiophene-3-carbonyl)piperidin-4-yl)methyl, ((5S,8s)-3,3-dimethyl-2-oxaspiro[4.5]decan-8-yl)methyl, (1,2,3,4-tetrahydronaphthalen-2-yl)methyl, (2,3-dihydro-1H-inden-2-yl)methyl, 2,6-difluoro-4-(tetrahydro-2H-pyran-4-yl)phenethyl, (1-(pyridin-3-yl)piperidin-4-yl)methyl, (1-(cyclohexylcarbamoyl)piperidin-4-yl)methyl, (1-(cyclohexylcarbamothioyl)piperidin-4-yl)methyl, (1-((1S,2R)-2-(trifluoromethyl)cyclohexyl)azetidin-3-yl)methyl, ((R)-1-phenylpyrrolidin-3-yl)methyl, ((R)-1-

(o-tolyl)pyrrolidin-3-yl)methyl, ((R)-1-(2-(trifluoromethyl)phenyl)pyrrolidin-3-yl)methyl, ((S)-1-(2-(trifluoromethyl)phenyl)pyrrolidin-3-yl)methyl, (R)-1-(2-fluorophenyl)pyrrolidin-3-yl)methyl, (R)-1-(3-fluorophenyl)pyrrolidin-3-yl)methyl, ((R)-1-(2-(trifluoromethoxy)phenyl)pyrrolidin-3-yl)methyl, ((R)-1-(6-(trifluoromethyl)pyridin-2-yl)pyrrolidin-3-yl)methyl, ((R)-1-(3-(trifluoromethyl)pyridin-2-yl)pyrrolidin-3-yl)methyl, ((R)-1-(4-(trifluoromethyl)pyridin-2-yl)pyrrolidin-3-yl)methyl, ((R)-1-(pyridin-3-yl)pyrrolidin-3-yl)methyl, ((R)-1-(4-methylpyridin-3-yl)pyrrolidin-3-yl)methyl, ((R)-1-(4-(trifluoromethyl)pyridin-3-yl)pyrrolidin-3-yl)methyl, ((R)-1-(5-(trifluoromethyl)pyridin-3-yl)pyrrolidin-3-yl)methyl, ((R)-1-(2-(trifluoromethyl)pyridin-3-yl)pyrrolidin-3-yl)methyl, ((R)-1-(4-(trifluoromethyl)pyrimidin-5-yl)pyrrolidin-3-yl)methyl, ((R)-1-(thiophen-3-yl)pyrrolidin-3-yl)methyl, ((R)-1-(benzo[d]thiazol-4-yl)pyrrolidin-3-yl)methyl, (S)-(1-(4-(trifluoromethyl)benzoyl)pyrrolidin-3-yl)methyl, ((R)-1-(o-tolyl)piperidin-3-yl)methyl, ((R)-1-(2-fluorophenyl)piperidin-3-yl)methyl, ((R)-1-(3-(trifluoromethyl)pyridin-2-yl)piperidin-3-yl)methyl, ((R)-1-(6-(trifluoromethyl)pyridin-2-yl)piperidin-3-yl)methyl, ((R)-1-(4-(trifluoromethyl)pyridin-3-yl)piperidin-3-yl)methyl, 3-fluorophenethyl, 4-fluorophenethyl, 3,4-dichlorophenethyl, 3-(trifluoromethyl)phenethyl, 4-(trifluoromethyl)phenethyl, ((R)-1-(benzo[d]thiazol-2-yl)pyrrolidin-3-yl)methyl, ((R)-1-(2-(trifluoromethyl)pyridin-3-yl)piperidin-3-yl)methyl, 4-(3,5-dimethylisoxazol-4-yl)-2,6-difluorophenethyl, 4-(3,5-dimethyl-1H-pyrazol-4-yl)-2,6-difluorophenethyl, ((R)-1-(4-(trifluoromethyl)thiazol-2-yl)pyrrolidin-3-yl)methyl, ((R)-1-(benzo[d]oxazol-2-yl)pyrrolidin-3-yl)methyl, ((R)-1-(5-isopropylthiazol-2-yl)piperidin-3-yl)methyl, ((R)-1-(4-(trifluoromethyl)thiazol-2-yl)piperidin-3-yl)methyl, ((R)-1-(benzo[d]thiazol-2-yl)piperidin-3-yl)methyl, ((R)-1-(benzo[d]thiazol-4-yl)piperidin-3-yl)methyl, ((S)-1-(3-(trifluoromethyl)pyridin-2-yl)pyrrolidin-3-yl)methyl, ((S)-1-(4-(trifluoromethyl)pyridin-3-yl)pyrrolidin-3-yl)methyl, ((S)-1-(4-(trifluoromethyl)pyrimidin-5-yl)pyrrolidin-3-yl)methyl, ((S)-1-(benzo[d]thiazol-4-yl)pyrrolidin-3-yl)methyl, ((S)-1-(3-(trifluoromethyl)pyridin-2-yl)piperidin-3-yl)methyl, ((S)-1-(4-(trifluoromethyl)pyridin-3-yl)piperidin-3-yl)methyl, ((S)-1-(6-(trifluoromethyl)pyridin-2-yl)piperidin-3-yl)methyl, ((S)-1-(benzo[d]thiazol-4-yl)piperidin-3-yl)methyl, ((R)-1-(5-(trifluoromethyl)pyridin-2-yl)pyrrolidin-3-yl)methyl, ((R)-1-(6-(trifluoromethyl)pyridin-3-yl)pyrrolidin-3-yl)methyl, ((R)-1-(3-(trifluoromethyl)pyridin-4-yl)pyrrolidin-3-yl)methyl, ((R)-1-(2-(trifluoromethyl)pyridin-4-yl)pyrrolidin-3-yl)methyl, ((S)-1-(2-(trifluoromethyl)pyridin-3-yl)pyrrolidin-3-yl)methyl, ((S)-1-

(5-(trifluoromethyl)pyridin-3-yl)pyrrolidin-3-yl)methyl, ((S)-1-(4-(trifluoromethyl)pyridin-2-yl)pyrrolidin-3-yl)methyl, ((S)-1-(6-(trifluoromethyl)pyridin-2-yl)pyrrolidin-3-yl)methyl, ((S)-1-(5-(trifluoromethyl)pyridin-2-yl)pyrrolidin-3-yl)methyl, ((S)-1-(6-(trifluoromethyl)pyridin-3-yl)pyrrolidin-3-yl)methyl, ((S)-1-(3-(trifluoromethyl)pyridin-4-yl)pyrrolidin-3-yl)methyl, ((S)-1-(2-(trifluoromethyl)pyridin-4-yl)pyrrolidin-3-yl)methyl, ((R)-1-(5-(trifluoromethyl)pyridin-3-yl)piperidin-3-yl)methyl, ((R)-1-(4-(trifluoromethyl)pyridin-2-yl)piperidin-3-yl)methyl, ((R)-1-(5-(trifluoromethyl)pyridin-2-yl)piperidin-3-yl)methyl, ((R)-1-(6-(trifluoromethyl)pyridin-3-yl)piperidin-3-yl)methyl, ((R)-1-(3-(trifluoromethyl)pyridin-4-yl)piperidin-3-yl)methyl, ((R)-1-(2-(trifluoromethyl)pyridin-4-yl)piperidin-3-yl)methyl, ((S)-1-(2-(trifluoromethyl)pyridin-3-yl)piperidin-3-yl)methyl, ((S)-1-(5-(trifluoromethyl)pyridin-3-yl)piperidin-3-yl)methyl, ((S)-1-(4-(trifluoromethyl)pyridin-2-yl)piperidin-3-yl)methyl, ((S)-1-(5-(trifluoromethyl)pyridin-2-yl)piperidin-3-yl)methyl, ((S)-1-(6-(trifluoromethyl)pyridin-3-yl)piperidin-3-yl)methyl, ((S)-1-(3-(trifluoromethyl)pyridin-4-yl)piperidin-3-yl)methyl, ((S)-1-(2-(trifluoromethyl)pyridin-4-yl)piperidin-3-yl)methyl, 1-(3-chloro-2-fluorophenyl)propan-2-yl, 4-(3-chloro-2-fluorophenyl)butan-2-yl, ((1r,4R)-4-(difluoromethyl)cyclohexyl)methyl, ((1s,4S)-4-(difluoromethyl)cyclohexyl)methyl, ((1s,4S)-4-(1,1-difluoroethyl)cyclohexyl)methyl, ((1r,4R)-4-(1,1-difluoroethyl)cyclohexyl)methyl, ((1r,4R)-4-(trifluoromethoxy)cyclohexyl)methyl, (4,7-difluoro-2,3-dihydro-1H-inden-2-yl)methyl, (1-(cyclohexanecarbonyl)-4-fluoropiperidin-4-yl)methyl, (4-fluoro-1-(4-fluorophenyl)piperidin-4-yl)methyl, (4-fluoro-1-(2-(trifluoromethyl)phenyl)piperidin-4-yl)methyl, (4-fluoro-1-(3-(trifluoromethyl)pyridin-2-yl)piperidin-4-yl)methyl, (4-fluoro-1-(6-(trifluoromethyl)pyridin-2-yl)piperidin-4-yl)methyl, (1-(benzo[d]thiazol-2-yl)-4-fluoropiperidin-4-yl)methyl, 4-butoxybenzyl, 4-(pentyloxy)benzyl, 4-butoxy-2,6-difluorobenzyl, 4-(cyclopropylmethoxy)benzyl, 4-phenoxybenzyl, [1,1'-biphenyl]-4-ylmethyl, 4-(pyrrolidin-1-yl)benzyl, 4-(piperidin-1-yl)benzyl, or thiophen-2-ylmethyl.

4. The compound of claim 1 wherein the compound is:

(3S,4R,5R)-1-(((1r,4R)-4-(trifluoromethyl)cyclohexyl)methyl)piperidine-3,4,5-triol;
(3S,4R,5R)-1-(((1s,4S)-4-(trifluoromethyl)cyclohexyl)methyl)piperidine-3,4,5-triol;
(3S,4R,5R)-1-(((1s,4S)-4-(2-fluoropropan-2-yl)cyclohexyl)methyl)piperidine-3,4,5-triol;
(3S,4r,5R)-1-(2-cyclohexylethyl)piperidine-3,4,5-triol;
(3S,4r,5R)-1-(3-cyclohexylpropyl)piperidine-3,4,5-triol;
(3S,4r,5R)-1-(3-chloro-2-fluorophenethyl)piperidine-3,4,5-triol;

(3S,4r,5R)-1-(3-chloro-2,6-difluorophenethyl)piperidine-3,4,5-triol;
(3S,4r,5R)-1-(3,4-dichlorophenethyl)piperidine-3,4,5-triol;
(3S,4r,5R)-1-(4-(cyclopropylmethoxy)-2,6-difluorophenethyl)piperidine-3,4,5-triol;
(3S,4r,5R)-1-(2,6-difluoro-4-(pyrrolidin-1-yl)phenethyl)piperidine-3,4,5-triol;
(3S,4r,5R)-1-(2,6-difluoro-4-(piperidin-1-yl)phenethyl)piperidine-3,4,5-triol;
(3S,4r,5R)-1-(2,6-difluoro-4-morpholinophenethyl)piperidine-3,4,5-triol;
(3S,4r,5R)-1-(2,6-difluoro-4-(tetrahydro-2H-pyran-4-yl)phenethyl)piperidine-3,4,5-triol;
(3S,4r,5R)-1-(4-(3,5-dimethylisoxazol-4-yl)-2,6-difluorophenethyl)piperidine-3,4,5-triol;
(3S,4r,5R)-1-(4-(3,5-dimethyl-1H-pyrazol-4-yl)-2,6-difluorophenethyl)piperidine-3,4,5-triol;
(3S,4r,5R)-1-(1-(3-chloro-2-fluorophenyl)propan-2-yl)piperidine-3,4,5-triol;
(3S,4r,5R)-1-(4-(3-chloro-2-fluorophenyl)butan-2-yl)piperidine-3,4,5-triol;
(3S,4R,5R)-1-(((R)-1-(o-tolyl)pyrrolidin-3-yl)methyl)piperidine-3,4,5-triol;
(3S,4R,5R)-1-(((R)-1-(3-(trifluoromethyl)pyridin-2-yl)pyrrolidin-3-yl)methyl)piperidine-3,4,5-triol;
(3S,4R,5R)-1-(((R)-1-(4-(trifluoromethyl)pyridin-3-yl)pyrrolidin-3-yl)methyl)piperidine-3,4,5-triol;
(3S,4R,5R)-1-(((R)-1-(4-(trifluoromethyl)thiazol-2-yl)pyrrolidin-3-yl)methyl)piperidine-3,4,5-triol;
(3S,4R,5R)-1-(((R)-1-(benzo[d]oxazol-2-yl)pyrrolidin-3-yl)methyl)piperidine-3,4,5-triol;
(3S,4R,5R)-1-(((R)-1-(benzo[d]thiazol-2-yl)pyrrolidin-3-yl)methyl)piperidine-3,4,5-triol;
(3S,4S,5R)-1-(((S)-1-(3-(trifluoromethyl)pyridin-2-yl)pyrrolidin-3-yl)methyl)piperidine-3,4,5-triol;
(3S,4S,5R)-1-(((S)-1-(4-(trifluoromethyl)pyridin-3-yl)pyrrolidin-3-yl)methyl)piperidine-3,4,5-triol;
(3S,4S,5R)-1-(((S)-1-(4-(trifluoromethyl)pyrimidin-5-yl)pyrrolidin-3-yl)methyl)piperidine-3,4,5-triol;
(3S,4S,5R)-1-(((S)-1-(4-(trifluoromethyl)thiazol-2-yl)pyrrolidin-3-yl)methyl)piperidine-3,4,5-triol;
(3S,4S,5R)-1-(((S)-1-(benzo[d]thiazol-4-yl)pyrrolidin-3-yl)methyl)piperidine-3,4,5-triol;
(3S,4R,5R)-1-(((R)-1-(3-(trifluoromethyl)pyridin-2-yl)piperidin-3-yl)methyl)piperidine-3,4,5-triol;

(3S,4R,5R)-1-(((R)-1-(6-(trifluoromethyl)pyridin-2-yl)piperidin-3-yl)methyl)piperidine-3,4,5-triol;

(3S,4R,5R)-1-(((R)-1-(2-(trifluoromethyl)pyridin-3-yl)piperidin-3-yl)methyl)piperidine-3,4,5-triol;

(3S,4R,5R)-1-(((R)-1-(5-isopropylthiazol-2-yl)piperidin-3-yl)methyl)piperidine-3,4,5-triol;

(3S,4R,5R)-1-(((R)-1-(4-(trifluoromethyl)thiazol-2-yl)piperidin-3-yl)methyl)piperidine-3,4,5-triol;

(3S,4R,5R)-1-(((R)-1-(benzo[d]thiazol-2-yl)piperidin-3-yl)methyl)piperidine-3,4,5-triol;

(3S,4R,5R)-1-(((R)-1-(benzo[d]thiazol-4-yl)piperidin-3-yl)methyl)piperidine-3,4,5-triol;

(3S,4S,5R)-1-(((S)-1-(3-(trifluoromethyl)pyridin-2-yl)piperidin-3-yl)methyl)piperidine-3,4,5-triol;

(3S,4S,5R)-1-(((S)-1-(6-(trifluoromethyl)pyridin-2-yl)piperidin-3-yl)methyl)piperidine-3,4,5-triol;

(3S,4S,5R)-1-(((S)-1-(4-(trifluoromethyl)pyridin-3-yl)piperidin-3-yl)methyl)piperidine-3,4,5-triol;

(3S,4S,5R)-1-(((S)-1-(4-(trifluoromethyl)thiazol-2-yl)piperidin-3-yl)methyl)piperidine-3,4,5-triol;

(3S,4r,5R)-1-(cyclohexylmethyl)piperidine-3,4,5-triol;

(3S,4r,5R)-1-((4,4-dimethylcyclohexyl)methyl)piperidine-3,4,5-triol;

(3S,4r,5R)-1-((4,4-difluorocyclohexyl)methyl)piperidine-3,4,5-triol;

(3S,4r,5R)-1-((4,4-dichlorocyclohexyl)methyl)piperidine-3,4,5-triol;

(3S,4r,5R)-1-((4-ethylcyclohexyl)methyl)piperidine-3,4,5-triol;

(3S,4R,5R)-1-(((1s,4S)-4-vinylcyclohexyl)methyl)piperidine-3,4,5-triol;

(3S,4R,5R)-1-(((1s,4S)-4-isopropylcyclohexyl)methyl)piperidine-3,4,5-triol;

(3S,4R,5R)-1-(((1r,4R)-4-isopropylcyclohexyl)methyl)piperidine-3,4,5-triol;

(3S,4R,5R)-1-(((1s,4S)-4-(tert-butyl)cyclohexyl)methyl)piperidine-3,4,5-triol;

(3S,4R,5R)-1-(((1r,4R)-4-(tert-butyl)cyclohexyl)methyl)piperidine-3,4,5-triol;

(3S,4R,5R)-1-(((1r,4R)-4-(2-fluoropropan-2-yl)cyclohexyl)methyl)piperidine-3,4,5-triol;

(3S,4R,5R)-1-(((1s,4S)-4-methoxycyclohexyl)methyl)piperidine-3,4,5-triol;

(3S,4R,5R)-1-(((1r,4R)-4-methoxycyclohexyl)methyl)piperidine-3,4,5-triol;

(3S,4r,5R)-1-((4-(methoxymethyl)cyclohexyl)methyl)piperidine-3,4,5-triol;

(3S,4R,5R)-1-(((1s,4S)-4-cyclopropylcyclohexyl)methyl)piperidine-3,4,5-triol;

(3S,4R,5R)-1-(((1r,4R)-4-cyclopropylcyclohexyl)methyl)piperidine-3,4,5-triol;

(3S,4r,5R)-1-((4-phenylcyclohexyl)methyl)piperidine-3,4,5-triol;

(3S,4r,5R)-1-(spiro[2.5]octan-6-ylmethyl)piperidine-3,4,5-triol;

(3S,4r,5R)-1-(spiro[3.5]nonan-7-ylmethyl)piperidine-3,4,5-triol;

(3S,4r,5R)-1-(spiro[4.5]decan-8-ylmethyl)piperidine-3,4,5-triol;

(3S,4R,5R)-1-(((5S,8s)-3,3-dimethyl-2-oxaspiro[4.5]decan-8-yl)methyl)piperidine-3,4,5-triol;

(3S,4r,5R)-1-((1,2,3,4-tetrahydronaphthalen-2-yl)methyl)piperidine-3,4,5-triol;

(3S,4r,5R)-1-((2,3-dihydro-1H-inden-2-yl)methyl)piperidine-3,4,5-triol;

(3S,4r,5R)-1-(2-(4,4-difluorocyclohexyl)ethyl)piperidine-3,4,5-triol;

(3S,4R,5R)-1-(2-((1s,4S)-4-(trifluoromethyl)cyclohexyl)ethyl)piperidine-3,4,5-triol;

(3S,4R,5R)-1-(2-((1r,4R)-4-(trifluoromethyl)cyclohexyl)ethyl)piperidine-3,4,5-triol;

(3S,4R,5R)-1-(2-((3R,5R,7R)-adamantan-1-yl)ethyl)piperidine-3,4,5-triol;

(3S,4r,5R)-1-phenethylpiperidine-3,4,5-triol;

(3S,4r,5R)-1-(2-methylphenethyl)piperidine-3,4,5-triol;

(3S,4r,5R)-1-(2-methoxyphenethyl)piperidine-3,4,5-triol;

(3S,4r,5R)-1-(2-fluorophenethyl)piperidine-3,4,5-triol;

(3S,4r,5R)-1-(2-chlorophenethyl)piperidine-3,4,5-triol;

(3S,4r,5R)-1-(2,3-difluorophenethyl)piperidine-3,4,5-triol;

(3S,4r,5R)-1-(2,4-difluorophenethyl)piperidine-3,4,5-triol;

(3S,4r,5R)-1-(2,5-difluorophenethyl)piperidine-3,4,5-triol;

(3S,4r,5R)-1-(3,4-difluorophenethyl)piperidine-3,4,5-triol;

(3S,4r,5R)-1-(2-fluoro-4-methoxyphenethyl)piperidine-3,4,5-triol;

(3S,4r,5R)-1-(4-chloro-2-fluorophenethyl)piperidine-3,4,5-triol;

(3S,4r,5R)-1-(5-chloro-2-fluorophenethyl)piperidine-3,4,5-triol;

(3S,4r,5R)-1-(2,6-difluorophenethyl)piperidine-3,4,5-triol;

(3S,4r,5R)-1-(2,6-difluoro-4-(prop-1-en-2-yl)phenethyl)piperidine-3,4,5-triol;

(3S,4r,5R)-1-(2,6-difluoro-4-isopropylphenethyl)piperidine-3,4,5-triol;

(3S,4r,5R)-1-(2,6-difluoro-3-isopropylphenethyl)piperidine-3,4,5-triol;

(3S,4r,5R)-1-(4-cyclopropyl-2,6-difluorophenethyl)piperidine-3,4,5-triol;

(3S,4r,5R)-1-(2,6-difluoro-4-(trifluoromethyl)phenethyl)piperidine-3,4,5-triol;

(3S,4r,5R)-1-(4-butoxy-2,6-difluorophenethyl)piperidine-3,4,5-triol;

(3S,4r,5R)-1-(4-((tetrahydrofuran-3-yl)oxy)phenethyl)piperidine-3,4,5-triol;

(3S,4r,5R)-1-(4-((tetrahydro-2H-pyran-3-yl)oxy)phenethyl)piperidine-3,4,5-triol;

(3S,4r,5R)-1-(4-((tetrahydro-2H-pyran-4-yl)oxy)phenethyl)piperidine-3,4,5-triol;

(3S,4r,5R)-1-(4-phenoxyphenethyl)piperidine-3,4,5-triol;

(3S,4r,5R)-1-(4-((tetrahydrofuran-3-yl)methoxy)phenethyl)piperidine-3,4,5-triol;

(3S,4R,5R)-1-((R)-2-phenylpropyl)piperidine-3,4,5-triol;

(3S,4S,5R)-1-((S)-2-phenylpropyl)piperidine-3,4,5-triol;

(3S,4r,5R)-1-(2-([1,1'-biphenyl]-4-yl)ethyl)piperidine-3,4,5-triol;

(3S,4r,5R)-1-(2-(3,5-difluoro-[1,1'-biphenyl]-4-yl)ethyl)piperidine-3,4,5-triol;

(3S,4r,5R)-1-(2-(benzo[d][1,3]dioxol-5-yl)ethyl)piperidine-3,4,5-triol;

(3S,4r,5R)-1-(2-(6-fluorobenzo[d][1,3]dioxol-5-yl)ethyl)piperidine-3,4,5-triol;

(3S,4r,5R)-1-(2-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)ethyl)piperidine-3,4,5-triol;

(3S,4r,5R)-1-(2-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)ethyl)piperidine-3,4,5-triol;

(3S,4r,5R)-1-(2-(thiophen-2-yl)ethyl)piperidine-3,4,5-triol;

(3S,4r,5R)-1-(2-(thiophen-3-yl)ethyl)piperidine-3,4,5-triol;

(3S,4r,5R)-1-(2-(pyridin-2-yl)ethyl)piperidine-3,4,5-triol;

(3S,4r,5R)-1-(3-(2-fluorophenyl)propyl)piperidine-3,4,5-triol;

(3S,4r,5R)-1-(3-(4-fluorophenyl)propyl)piperidine-3,4,5-triol;

(3S,4r,5R)-1-(3-(thiophen-2-yl)propyl)piperidine-3,4,5-triol;

(3S,4r,5R)-1-(3-(thiophen-3-yl)propyl)piperidine-3,4,5-triol;

(3S,4r,5R)-1-((1-phenylpiperidin-4-yl)methyl)piperidine-3,4,5-triol;

(3S,4r,5R)-1-((1-(2-fluorophenyl)piperidin-4-yl)methyl)piperidine-3,4,5-triol;

(3S,4r,5R)-1-((1-(3-fluorophenyl)piperidin-4-yl)methyl)piperidine-3,4,5-triol;

(3S,4r,5R)-1-((1-(4-fluorophenyl)piperidin-4-yl)methyl)piperidine-3,4,5-triol;

(3S,4r,5R)-1-((1-(4-(trifluoromethyl)phenyl)piperidin-4-yl)methyl)piperidine-3,4,5-triol;

(3S,4r,5R)-1-((4-methyl-1-phenylpiperidin-4-yl)methyl)piperidine-3,4,5-triol;

(3S,4r,5R)-1-((4-fluoro-1-phenylpiperidin-4-yl)methyl)piperidine-3,4,5-triol;

(3S,4r,5R)-1-(2-(1-phenylpiperidin-4-yl)ethyl)piperidine-3,4,5-triol;

(3S,4r,5R)-1-((1-(pyridin-3-yl)piperidin-4-yl)methyl)piperidine-3,4,5-triol;

(3S,4r,5R)-1-((1-(2,2,2-trifluoroethyl)piperidin-4-yl)methyl)piperidine-3,4,5-triol;

2-methyl-1-(4-(((3S,4r,5R)-3,4,5-trihydroxypiperidin-1-yl)methyl)piperidin-1-yl)propan-1-one;
2,2-dimethyl-1-(4-(((3S,4r,5R)-3,4,5-trihydroxypiperidin-1-yl)methyl)piperidin-1-yl)propan-1-one;
1-(4-(((3S,4r,5R)-3,4,5-trihydroxypiperidin-1-yl)methyl)piperidin-1-yl)butan-1-one;
3-methyl-1-(4-(((3S,4r,5R)-3,4,5-trihydroxypiperidin-1-yl)methyl)piperidin-1-yl)butan-1-one;
3,3-dimethyl-1-(4-(((3S,4r,5R)-3,4,5-trihydroxypiperidin-1-yl)methyl)piperidin-1-yl)butan-1-one;
2-cyclopentyl-1-(4-(((3S,4r,5R)-3,4,5-trihydroxypiperidin-1-yl)methyl)piperidin-1-yl)ethanone;
cyclopropyl(4-(((3S,4r,5R)-3,4,5-trihydroxypiperidin-1-yl)methyl)piperidin-1-yl)methanone;
cyclobutyl(4-(((3S,4r,5R)-3,4,5-trihydroxypiperidin-1-yl)methyl)piperidin-1-yl)methanone;
cyclopentyl(4-(((3S,4r,5R)-3,4,5-trihydroxypiperidin-1-yl)methyl)piperidin-1-yl)methanone;
cyclohexyl(4-(((3S,4r,5R)-3,4,5-trihydroxypiperidin-1-yl)methyl)piperidin-1-yl)methanone;
((1s,4S)-4-(tert-butyl)cyclohexyl)(4-(((3S,4R,5R)-3,4,5-trihydroxypiperidin-1-yl)methyl)piperidin-1-yl)methanone;
((1r,4R)-4-(tert-butyl)cyclohexyl)(4-(((3S,4R,5R)-3,4,5-trihydroxypiperidin-1-yl)methyl)piperidin-1-yl)methanone;
(4-methoxycyclohexyl)(4-(((3S,4r,5R)-3,4,5-trihydroxypiperidin-1-yl)methyl)piperidin-1-yl)methanone;
(4-(trifluoromethyl)cyclohexyl)(4-(((3S,4r,5R)-3,4,5-trihydroxypiperidin-1-yl)methyl)piperidin-1-yl)methanone;
phenyl(4-(((3S,4r,5R)-3,4,5-trihydroxypiperidin-1-yl)methyl)piperidin-1-yl)methanone;
(3-(trifluoromethyl)phenyl)(4-(((3S,4r,5R)-3,4,5-trihydroxypiperidin-1-yl)methyl)piperidin-1-yl)methanone;
2-phenyl-1-(4-(((3S,4r,5R)-3,4,5-trihydroxypiperidin-1-yl)methyl)piperidin-1-yl)ethanone;
thiophen-3-yl(4-(((3S,4r,5R)-3,4,5-trihydroxypiperidin-1-yl)methyl)piperidin-1-yl)methanone;
N-cyclohexyl-4-(((3S,4r,5R)-3,4,5-trihydroxypiperidin-1-yl)methyl)piperidine-1-carboxamide;
N-cyclohexyl-4-(((3S,4r,5R)-3,4,5-trihydroxypiperidin-1-yl)methyl)piperidine-1-carbothioamide;
(3S,4S,5R)-1-((1-((1S,2R)-2-(trifluoromethyl)cyclohexyl)azetidin-3-yl)methyl)piperidine-3,4,5-triol;
(3S,4R,5R)-1-(((R)-1-phenylpyrrolidin-3-yl)methyl)piperidine-3,4,5-triol;

(3S,4R,5R)-1-(((R)-1-(2-(trifluoromethyl)phenyl)pyrrolidin-3-yl)methyl)piperidine-3,4,5-triol;
(3S,4R,5R)-1-(((R)-1-(2-fluorophenyl)pyrrolidin-3-yl)methyl)piperidine-3,4,5-triol;
(3S,4R,5R)-1-(((R)-1-(3-fluorophenyl)pyrrolidin-3-yl)methyl)piperidine-3,4,5-triol;
(3S,4R,5R)-1-(((R)-1-(2-(trifluoromethoxy)phenyl)pyrrolidin-3-yl)methyl)piperidine-3,4,5-triol;
(3S,4R,5R)-1-(((R)-1-(6-(trifluoromethyl)pyridin-2-yl)pyrrolidin-3-yl)methyl)piperidine-3,4,5-triol;
(3S,4R,5R)-1-(((R)-1-(4-(trifluoromethyl)pyridin-2-yl)pyrrolidin-3-yl)methyl)piperidine-3,4,5-triol;
(3S,4R,5R)-1-(((R)-1-(pyridin-3-yl)pyrrolidin-3-yl)methyl)piperidine-3,4,5-triol;
(3S,4R,5R)-1-(((R)-1-(4-methylpyridin-3-yl)pyrrolidin-3-yl)methyl)piperidine-3,4,5-triol;
(3S,4R,5R)-1-(((R)-1-(5-(trifluoromethyl)pyridin-3-yl)pyrrolidin-3-yl)methyl)piperidine-3,4,5-triol;
(3S,4R,5R)-1-(((R)-1-(2-(trifluoromethyl)pyridin-3-yl)pyrrolidin-3-yl)methyl)piperidine-3,4,5-triol;
(3S,4R,5R)-1-(((R)-1-(5-(trifluoromethyl)pyridin-2-yl)pyrrolidin-3-yl)methyl)piperidine-3,4,5-triol;
(3S,4R,5R)-1-(((R)-1-(6-(trifluoromethyl)pyridin-3-yl)pyrrolidin-3-yl)methyl)piperidine-3,4,5-triol;
(3S,4R,5R)-1-(((R)-1-(3-(trifluoromethyl)pyridin-4-yl)pyrrolidin-3-yl)methyl)piperidine-3,4,5-triol;
(3S,4R,5R)-1-(((R)-1-(2-(trifluoromethyl)pyridin-4-yl)pyrrolidin-3-yl)methyl)piperidine-3,4,5-triol;
(3S,4R,5R)-1-(((R)-1-(4-(trifluoromethyl)pyrimidin-5-yl)pyrrolidin-3-yl)methyl)piperidine-3,4,5-triol;
(3R,4R,5S)-1-(((R)-1-(thiophen-3-yl)pyrrolidin-3-yl)methyl)piperidine-3,4,5-triol;
(3S,4R,5R)-1-(((R)-1-(benzo[d]thiazol-4-yl)pyrrolidin-3-yl)methyl)piperidine-3,4,5-triol;
(4-(trifluoromethyl)phenyl)((R)-3-(((3S,4R,5R)-3,4,5-trihydroxypiperidin-1-yl)methyl)pyrrolidin-1-yl)methanone;
(3S,4S,5R)-1-(((S)-1-(2-(trifluoromethyl)phenyl)pyrrolidin-3-yl)methyl)piperidine-3,4,5-triol;
(3S,4S,5R)-1-(((S)-1-(6-(trifluoromethyl)pyridin-2-yl)pyrrolidin-3-yl)methyl)piperidine-3,4,5-triol;

(3S,4S,5R)-1-(((S)-1-(2-(trifluoromethyl)pyridin-3-yl)pyrrolidin-3-yl)methyl)piperidine-3,4,5-triol;

(3S,4S,5R)-1-(((S)-1-(5-(trifluoromethyl)pyridin-3-yl)pyrrolidin-3-yl)methyl)piperidine-3,4,5-triol;

(3S,4S,5R)-1-(((S)-1-(4-(trifluoromethyl)pyridin-2-yl)pyrrolidin-3-yl)methyl)piperidine-3,4,5-triol;

(3S,4S,5R)-1-(((S)-1-(5-(trifluoromethyl)pyridin-2-yl)pyrrolidin-3-yl)methyl)piperidine-3,4,5-triol;

(3S,4S,5R)-1-(((S)-1-(6-(trifluoromethyl)pyridin-3-yl)pyrrolidin-3-yl)methyl)piperidine-3,4,5-triol;

(3S,4S,5R)-1-(((S)-1-(3-(trifluoromethyl)pyridin-4-yl)pyrrolidin-3-yl)methyl)piperidine-3,4,5-triol;

(3S,4S,5R)-1-(((S)-1-(2-(trifluoromethyl)pyridin-4-yl)pyrrolidin-3-yl)methyl)piperidine-3,4,5-triol;

(3S,4R,5R)-1-(((R)-1-(o-tolyl)piperidin-3-yl)methyl)piperidine-3,4,5-triol;

(3S,4R,5R)-1-(((R)-1-(2-fluorophenyl)piperidin-3-yl)methyl)piperidine-3,4,5-triol;

(3S,4R,5R)-1-(((R)-1-(4-(trifluoromethyl)pyridin-3-yl)piperidin-3-yl)methyl)piperidine-3,4,5-triol;

(3S,4R,5R)-1-(((R)-1-(5-(trifluoromethyl)pyridin-3-yl)piperidin-3-yl)methyl)piperidine-3,4,5-triol;

(3S,4R,5R)-1-(((R)-1-(4-(trifluoromethyl)pyridin-2-yl)piperidin-3-yl)methyl)piperidine-3,4,5-triol;

(3S,4R,5R)-1-(((R)-1-(5-(trifluoromethyl)pyridin-2-yl)piperidin-3-yl)methyl)piperidine-3,4,5-triol;

(3S,4R,5R)-1-(((R)-1-(6-(trifluoromethyl)pyridin-3-yl)piperidin-3-yl)methyl)piperidine-3,4,5-triol;

(3S,4R,5R)-1-(((R)-1-(3-(trifluoromethyl)pyridin-4-yl)piperidin-3-yl)methyl)piperidine-3,4,5-triol;

(3S,4R,5R)-1-(((R)-1-(2-(trifluoromethyl)pyridin-4-yl)piperidin-3-yl)methyl)piperidine-3,4,5-triol;

(3S,4S,5R)-1-(((S)-1-(2-(trifluoromethyl)pyridin-3-yl)piperidin-3-yl)methyl)piperidine-3,4,5-triol;
(3S,4S,5R)-1-(((S)-1-(5-(trifluoromethyl)pyridin-3-yl)piperidin-3-yl)methyl)piperidine-3,4,5-triol;
(3S,4S,5R)-1-(((S)-1-(4-(trifluoromethyl)pyridin-2-yl)piperidin-3-yl)methyl)piperidine-3,4,5-triol;
(3S,4S,5R)-1-(((S)-1-(5-(trifluoromethyl)pyridin-2-yl)piperidin-3-yl)methyl)piperidine-3,4,5-triol;
(3S,4S,5R)-1-(((S)-1-(6-(trifluoromethyl)pyridin-3-yl)piperidin-3-yl)methyl)piperidine-3,4,5-triol;
(3S,4S,5R)-1-(((S)-1-(3-(trifluoromethyl)pyridin-4-yl)piperidin-3-yl)methyl)piperidine-3,4,5-triol;
(3S,4S,5R)-1-(((S)-1-(2-(trifluoromethyl)pyridin-4-yl)piperidin-3-yl)methyl)piperidine-3,4,5-triol;
(3S,4r,5R)-1-(3-fluorophenethyl)piperidine-3,4,5-triol;
(3S,4r,5R)-1-(4-fluorophenethyl)piperidine-3,4,5-triol;
(3S,4r,5R)-1-(3-(trifluoromethyl)phenethyl)piperidine-3,4,5-triol;
(3S,4r,5R)-1-(4-(trifluoromethyl)phenethyl)piperidine-3,4,5-triol;
(3S,4R,5R)-1-(((1r,4R)-4-(difluoromethyl)cyclohexyl)methyl)piperidine-3,4,5-triol;
(3S,4R,5R)-1-(((1s,4S)-4-(difluoromethyl)cyclohexyl)methyl)piperidine-3,4,5-triol;
(3S,4R,5R)-1-(((1s,4S)-4-(1,1-difluoroethyl)cyclohexyl)methyl)piperidine-3,4,5-triol;
(3S,4R,5R)-1-(((1r,4R)-4-(1,1-difluoroethyl)cyclohexyl)methyl)piperidine-3,4,5-triol;
(3S,4R,5R)-1-(((1r,4R)-4-(trifluoromethoxy)cyclohexyl)methyl)piperidine-3,4,5-triol;
(3S,4r,5R)-1-((4,7-difluoro-2,3-dihydro-1H-inden-2-yl)methyl)piperidine-3,4,5-triol;
cyclohexyl(4-fluoro-4-(((3S,4r,5R)-3,4,5-trihydroxypiperidin-1-yl)methyl)piperidin-1-yl)methanone;
(3S,4r,5R)-1-((4-fluoro-1-(4-fluorophenyl)piperidin-4-yl)methyl)piperidine-3,4,5-triol;
(3S,4r,5R)-1-((4-fluoro-1-(2-(trifluoromethyl)phenyl)piperidin-4-yl)methyl)piperidine-3,4,5-triol;
(3S,4r,5R)-1-((4-fluoro-1-(3-(trifluoromethyl)pyridin-2-yl)piperidin-4-yl)methyl)piperidine-3,4,5-triol;

(3S,4r,5R)-1-((4-fluoro-1-(6-(trifluoromethyl)pyridin-2-yl)piperidin-4-yl)methyl)piperidine-3,4,5-triol;

(3S,4r,5R)-1-((1-(benzo[d]thiazol-2-yl)-4-fluoropiperidin-4-yl)methyl)piperidine-3,4,5-triol;

(3S,4r,5R)-1-(4-butoxybenzyl)piperidine-3,4,5-triol;

(3S,4r,5R)-1-(4-(pentyloxy)benzyl)piperidine-3,4,5-triol;

(3S,4r,5R)-1-(4-butoxy-2,6-difluorobenzyl)piperidine-3,4,5-triol;

(3S,4r,5R)-1-(4-(cyclopropylmethoxy)benzyl)piperidine-3,4,5-triol;

(3S,4r,5R)-1-(4-phenoxybenzyl)piperidine-3,4,5-triol;

(3S,4r,5R)-1-([1,1'-biphenyl]-4-ylmethyl)piperidine-3,4,5-triol;

(3S,4r,5R)-1-(4-(pyrrolidin-1-yl)benzyl)piperidine-3,4,5-triol;

(3S,4r,5R)-1-(4-(piperidin-1-yl)benzyl)piperidine-3,4,5-triol;

(3S,4r,5R)-1-(thiophen-2-ylmethyl)piperidine-3,4,5-triol;

or a pharmaceutically acceptable salt of any of the foregoing compounds.

5. The compound of claim 1 wherein the compound is a prodrug.

6. The compound of any one of claims 1 to 5 wherein the compound inhibits a non-lysosomal glucosylceramidase (GBA2), specifically binds a GBA2 and/or decreases the enzyme activity levels of a GBA2.

7. The compound of claim 6 wherein the GBA2 is a mammalian GBA2.

8. A pharmaceutical composition comprising the compound of any one of claims 1 to 7 or a pharmaceutically acceptable salt thereof in combination with a pharmaceutically acceptable carrier.

9. Use of a compound of Formula (I) or a pharmaceutically acceptable salt thereof:



(I)

wherein

R^1 is $(CH_2)_nR^2$, wherein n is 1, 2, or 3, and R^2 is cyclohexyl, phenyl, thiophen-2-yl, thiophen-3-yl, pyridine-2-yl, adamantyl, 2,3-dihydro-1H-inden-2-yl, 1,2,3,4-tetrahydronaphthalen-2-yl, spiro[2.5]octan-6-yl, spiro[3.5]nonan-7-yl, spiro[4.5]decan-8-yl, (5S,8s)-3,3-dimethyl-2-oxaspiro[4.5]decan-8-yl, (benzo[d][1,3]dioxol-5-yl)methyl, (2,3-dihydrobenzo[b][1,4]dioxin-6-yl)methyl, 1-cyclohexylazetidin-3-yl,

 ,  , or  each optionally substituted from one up to the maximum number of substituents with one or more of F, Cl, C_{1-6} alkyl, C_{2-6} alkenyl, cyclopropyl, difluoromethyl, 1,1-difluoroethyl-1-yl, 2-fluoropropan-2-yl, methoxymethyl, OCF_3, CF_3, phenyl, pyrrolidin-1-yl, piperidin-1-yl, 4-morpholino, C_{1-6} alkoxy, cyclopropylmethoxy, (tetrahydrofuran-3-yl)oxy, (tetrahydro-2H-pyran-3-yl)oxy, (tetrahydro-2H-pyran-4-yl)oxy, phenoxy, (tetrahydrofuran-3-yl)methoxy, tetrahydro-2H-pyran-4-yl, 3,5-dimethylisoxazol-4-yl, and/or 3,5-dimethyl-1H-pyrazol-4-yl;

where R^3 is C_{1-6} alkyl, phenyl, pyridine-2-yl, pyridin-3-yl, benzo[d]thiazol-2-yl, cyclohexylcarbamothioyl, or cyclohexylcarbamoyl, each optionally substituted from one up to the maximum number of substituents with one or more of F, Cl, C_{1-6} alkyl, C_{2-6} alkenyl, cyclopropyl, C_{1-6} alkoxy, OCF_3, and/or CF_3; and

where R^4 is C_{1-6} alkyl, C_{3-7} cycloalkyl, phenyl, thiophen-3-yl, phenylmethyl, or cyclopentylmethyl, each optionally substituted from one up to the maximum number of substituents with one or more of F, C_{1-6} alkyl, OCH_3, and/or CF_3; and

where m is 1 or 2; and

where R^5 is phenyl, pyridin-2-yl, pyridin-3-yl, pyridin-4-yl, pyrimidin-5-yl, thiophen-3-yl, benzo[d]thiazol-4-yl, benzo[d]thiazol-2-yl, phenylcarbonyl, thiazol-2-yl, benzo[d]oxazol-2-yl, or benzo[d]thiazol-2-yl, each optionally substituted from one up to the maximum number of substituents with one or more of F, Cl, C_{1-6} alkyl, C_{1-6} alkoxyl, OCF_3, and/or CF_3,

with the proviso that R^1 is not benzyl or 3-phenylpropyl,

in the preparation of a medicament for inhibiting a GBA2 in a subject in need thereof.

10. Use of a compound of Formula (I) or a pharmaceutically acceptable salt thereof:



(I)

wherein

R^1 is $(CH_2)_nR^2$, wherein n is 1, 2, or 3, and R^2 is cyclohexyl, phenyl, thiophen-2-yl, thiophen-3-yl, pyridine-2-yl, adamantyl, 2,3-dihydro-1H-inden-2-yl, 1,2,3,4-tetrahydronaphthalen-2-yl, spiro[2.5]octan-6-yl, spiro[3.5]nonan-7-yl, spiro[4.5]decan-8-yl, (5S,8s)-3,3-dimethyl-2-oxaspiro[4.5]decan-8-yl, (benzo[d][1,3]dioxol-5-yl)methyl, (2,3-dihydrobenzo[b][1,4]dioxin-6-yl)methyl, 1-cyclohexylazetidin-3-yl,

 ,  , or  each optionally substituted from one up to the maximum number of substituents with one or more of F, Cl, C_{1-6} alkyl, C_{2-6} alkenyl, cyclopropyl, difluoromethyl, 1,1-difluoroethyl-1-yl, 2-fluoropropan-2-yl, methoxymethyl, OCF_3, CF_3, phenyl, pyrrolidin-1-yl, piperidin-1-yl, 4-morpholino, C_{1-6} alkoxy, cyclopropylmethoxy, (tetrahydrofuran-3-yl)oxy, (tetrahydro-2H-pyran-3-yl)oxy, (tetrahydro-2H-pyran-4-yl)oxy, phenoxy, (tetrahydrofuran-3-yl)methoxy, tetrahydro-2H-pyran-4-yl, 3,5-dimethylisoxazol-4-yl, and/or 3,5-dimethyl-1H-pyrazol-4-yl;

where R^3 is C_{1-6} alkyl, phenyl, pyridine-2-yl, pyridin-3-yl, benzo[d]thiazol-2-yl, cyclohexylcarbamothioyl, or cyclohexylcarbamoyl, each optionally substituted from one up to the maximum number of substituents with one or more of F, Cl, C_{1-6} alkyl, C_{2-6} alkenyl, cyclopropyl, C_{1-6} alkoxy, OCF_3, and/or CF_3; and

where R^4 is C_{1-6} alkyl, C_{3-7} cycloalkyl, phenyl, thiophen-3-yl, phenylmethyl, or cyclopentylmethyl, each optionally substituted from one up to the maximum number of substituents with one or more of F, C_{1-6} alkyl, OCH_3, and/or CF_3; and

where m is 1 or 2; and

where R^5 is phenyl, pyridin-2-yl, pyridin-3-yl, pyridin-4-yl, pyrimidin-5-yl, thiophen-3-yl, benzo[d]thiazol-4-yl, benzo[d]thiazol-2-yl, phenylcarbonyl, thiazol-2-yl, benzo[d]oxazol-2-yl, or benzo[d]thiazol-2-yl, each optionally substituted from one up to the maximum number of substituents with one or more of F, Cl, C_{1-6} alkyl, C_{1-6} alkoxyl, OCF_3, and/or CF_3,

with the proviso that R^1 is not benzyl or 3-phenylpropyl,

in the preparation of a medicament for reducing the GBA2 enzyme activity in a subject in need thereof.

11. Use of a compound of Formula (I) or a pharmaceutically acceptable salt thereof:



(I)

wherein

R^1 is $(CH_2)_nR^2$, wherein n is 1, 2, or 3, and R^2 is cyclohexyl, phenyl, thiophen-2-yl, thiophen-3-yl, pyridine-2-yl, adamantyl, 2,3-dihydro-1H-inden-2-yl, 1,2,3,4-tetrahydronaphthalen-2-yl, spiro[2.5]octan-6-yl, spiro[3.5]nonan-7-yl, spiro[4.5]decan-8-yl, (5S,8s)-3,3-dimethyl-2-oxaspiro[4.5]decan-8-yl, (benzo[d][1,3]dioxol-5-yl)methyl, (2,3-dihydrobenzo[b][1,4]dioxin-6-yl)methyl, 1-cyclohexylazetidin-3-yl,

 ,  , or  each optionally substituted from one up to the maximum number of substituents with one or more of F, Cl, C_{1-6} alkyl, C_{2-6} alkenyl, cyclopropyl, difluoromethyl, 1,1-difluoroethyl-1-yl, 2-fluoropropan-2-yl, methoxymethyl, OCF_3, CF_3, phenyl, pyrrolidin-1-yl, piperidin-1-yl, 4-morpholino, C_{1-6} alkoxy, cyclopropylmethoxy, (tetrahydrofuran-3-yl)oxy, (tetrahydro-2H-pyran-3-yl)oxy, (tetrahydro-2H-pyran-4-yl)oxy, phenoxy, (tetrahydrofuran-3-yl)methoxy, tetrahydro-2H-pyran-4-yl, 3,5-dimethylisoxazol-4-yl, and/or 3,5-dimethyl-1H-pyrazol-4-yl;

where R^3 is C_{1-6} alkyl, phenyl, pyridine-2-yl, pyridin-3-yl, benzo[d]thiazol-2-yl, cyclohexylcarbamothioyl, or cyclohexylcarbamoyl, each optionally substituted from one up to the maximum number of substituents with one or more of F, Cl, C_{1-6} alkyl, C_{2-6} alkenyl, cyclopropyl, C_{1-6} alkoxy, OCF_3, and/or CF_3; and

where R^4 is C_{1-6} alkyl, C_{3-7} cycloalkyl, phenyl, thiophen-3-yl, phenylmethyl, or cyclopentylmethyl, each optionally substituted from one up to the maximum number of substituents with one or more of F, C_{1-6} alkyl, OCH_3, and/or CF_3; and

where m is 1 or 2; and

where R^5 is phenyl, pyridin-2-yl, pyridin-3-yl, pyridin-4-yl, pyrimidin-5-yl, thiophen-3-yl, benzo[d]thiazol-4-yl, benzo[d]thiazol-2-yl, phenylcarbonyl, thiazol-2-yl, benzo[d]oxazol-2-yl, or benzo[d]thiazol-2-yl, each optionally substituted from one up to the maximum number of substituents with one or more of F, Cl, C_{1-6} alkyl, C_{1-6} alkoxyl, OCF_3, and/or CF_3,

with the proviso that R^1 is not benzyl or 3-phenylpropyl,

in the preparation of a medicament for treating a condition that is modulated by a GBA2, in a subject in need thereof.

12. Use of a compound of Formula (I) or a pharmaceutically acceptable salt thereof:



(I)

wherein

R^1 is $(CH_2)_nR^2$, wherein n is 1, 2, or 3, and R^2 is cyclohexyl, phenyl, thiophen-2-yl, thiophen-3-yl, pyridine-2-yl, adamantyl, 2,3-dihydro-1H-inden-2-yl, 1,2,3,4-tetrahydronaphthalen-2-yl, spiro[2.5]octan-6-yl, spiro[3.5]nonan-7-yl, spiro[4.5]decan-8-yl, (5S,8s)-3,3-dimethyl-2-oxaspiro[4.5]decan-8-yl, (benzo[d][1,3]dioxol-5-yl)methyl, (2,3-dihydrobenzo[b][1,4]dioxin-6-yl)methyl, 1-cyclohexylazetidin-3-yl,

 , , or  each optionally substituted from one up to the maximum number of substituents with one or more of F, Cl, C_{1-6} alkyl, C_{2-6} alkenyl, cyclopropyl, difluoromethyl, 1,1-difluoroethyl-1-yl, 2-fluoropropan-2-yl, methoxymethyl, OCF_3, CF_3, phenyl, pyrrolidin-1-yl, piperidin-1-yl, 4-morpholino, C_{1-6} alkoxy, cyclopropylmethoxy, (tetrahydrofuran-3-yl)oxy, (tetrahydro-2H-pyran-3-yl)oxy, (tetrahydro-2H-pyran-4-yl)oxy, phenoxy, (tetrahydrofuran-3-yl)methoxy, tetrahydro-2H-pyran-4-yl, 3,5-dimethylisoxazol-4-yl, and/or 3,5-dimethyl-1H-pyrazol-4-yl;

where R^3 is C_{1-6} alkyl, phenyl, pyridine-2-yl, pyridin-3-yl, benzo[d]thiazol-2-yl, cyclohexylcarbamothioyl, or cyclohexylcarbamoyl, each optionally substituted from one up to the maximum number of substituents with one or more of F, Cl, C_{1-6} alkyl, C_{2-6} alkenyl, cyclopropyl, C_{1-6} alkoxy, OCF_3, and/or CF_3; and

where R^4 is C_{1-6} alkyl, C_{3-7} cycloalkyl, phenyl, thiophen-3-yl, phenylmethyl, or cyclopentylmethyl, each optionally substituted from one up to the maximum number of substituents with one or more of F, C_{1-6} alkyl, OCH_3, and/or CF_3; and

where m is 1 or 2; and

where R^5 is phenyl, pyridin-2-yl, pyridin-3-yl, pyridin-4-yl, pyrimidin-5-yl, thiophen-3-yl, benzo[d]thiazol-4-yl, benzo[d]thiazol-2-yl, phenylcarbonyl, thiazol-2-yl, benzo[d]oxazol-2-yl, or benzo[d]thiazol-2-yl, each optionally substituted from one up to the maximum number of substituents with one or more of F, Cl, C_{1-6} alkyl, C_{1-6} alkoxyl, OCF_3, and/or CF_3,

with the proviso that R^1 is not benzyl or 3-phenylpropyl,

in the preparation of a medicament for treating a condition selected from a neurological disease, a lysosomal storage disease, and a liver disease, in a subject in need thereof.

13. The use of claim 11 or 12 wherein the condition is Alzheimer's disease, Parkinson's disease, multiple sclerosis, Huntington's disease, amyotrophic lateral sclerosis (ALS), amyotrophic lateral sclerosis with cognitive impairment (ALSci), addiction, anxiety, argyrophilic grain dementia, ataxia-telangiectasia (A-T), attention deficit/hyperactivity disorder (ADHD), autism spectrum disorder (ASD), Becker muscular dystrophy (BMD), bipolar disorder (BD),

Bluit disease, cerebellar ataxia, Charcot-Marie-Tooth disease (CMT), chronic fatigue syndrome, corticobasal degeneration (CBD), dementia pugilistica, dementia with Lewy bodies (DLB), Dejerine-Sottas disease, diffuse neurofibrillary tangles with calcification, Down's syndrome, Duchenne muscular dystrophy (DMD), epilepsy, essential tremor (ET), familial British dementia, familial Danish dementia, fibromyalgia, frontotemporal dementia with parkinsonism linked to chromosome 17 (FTDP-17), Friedreich's ataxia, Gerstmann-Straussler-Scheinker disease, glaucoma, Guadeloupean parkinsonism, Guillain-Barré syndrome, Hallevorden-Spatz disease (neurodegeneration with brain iron accumulation type 1), insomnia, Lambert-Eaton myasthenic syndrome (LEMS), major depressive disorder (MDD), migraine, mild cognitive impairment (MCI), multi-infarct dementia, multiple system atrophy (MSA), myasthenia gravis, myotonic dystrophy (including types DM1 and DM2), neuronal ceroid lipofuscinosis (including types 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10), neuropathy (including peripheral neuropathy, autonomic neuropathy, neuritis, and diabetic neuropathy), oculopharyngeal muscular dystrophy, pain, pallido-ponto-nigral degeneration, parkinsonism-dementia complex of Guam, Pick's disease (PiD), post-encephalitic parkinsonism (PEP), primary lateral sclerosis (PLS), prion diseases (including Creutzfeldt-Jakob Disease (CJD), variant Creutzfeldt-Jakob Disease (vCJD), fatal familial insomnia, and kuru), progressive supercortical gliosis, progressive supranuclear palsy (PSP), Richardson's syndrome, schizophrenia, seizures, spinal cord injury, spinal muscular atrophy (SMA), spinocerebellar ataxia (including types 1, 2, 3, 4, 5, 6, 7, 8, 10, 11, 12, 13, 14, 16, 17, 18, 19, 20, 21, 22, 23, 25, 26, 27, 28, and 29), stroke, subacute sclerosing panencephalitis, tangle-only dementia, tardive dyskinesia, Tourette syndrome (TS), vascular dementia, Wilson's disease, Gaucher disease (including types I, II, and III), Niemann-Pick disease (including types A, B, and C), mucolipidosis (including types I, II, III, IV, VI, and VII), cerebrotendineous xanthomatosis, Fabry disease, Farber disease, GM1 gangliosidosis, Krabbe disease, metachromatic leukodystrophy (MLD), multiple sulfatase deficiency, Pompe disease, Sandhoff disease, Tay-Sach's disease, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), Alagille syndrome, alcohol-related liver disease, alpha-1 antitrypsin deficiency, autoimmune hepatitis, autoimmune cholangitis, benign liver tumors, biliary atresia, cirrhosis, Crigler-Najjar syndrome, drug-induced liver injury (DILI), galactosemia, Gilbert syndrome, hemochromatosis, hepatic encephalopathy, hepatocellular carcinoma (HCC), intrahepatic cholestasis of pregnancy (ICP), lysosomal acid lipase deficiency (LAL-D), liver

cysts, liver cancer, newborn jaundice, primary biliary cholangitis (PBC), primary sclerosing cholangitis (PSC), Reye syndrome, type I glycogen storage disease, or viral hepatitis (including types A, B, C, D, and E).

14. The use of claim 11 or 12 wherein the condition is Parkinson's disease.

15. The use of claim 11 or 12 wherein the condition is Alzheimer's disease, Huntington's disease, amyotrophic lateral sclerosis (ALS), or multiple sclerosis.

16. The use of claim 11 or 12 wherein the condition is Niemann-Pick type C disease, Gaucher disease, mucolipidosis type IV, neuronal ceroid lipofuscinosis, or Sandhoff disease.

17. The use of claim 11 or 12 wherein the condition is non-alcoholic steatohepatitis (NASH).

18. The use of any one of claims 9 to 17 wherein the compound is one or more of the compounds described in Table 1.

19. The use of any one of claims 9 to 18 wherein said compound decreases the level of GBA2 enzyme activity in the subject.

20. The use of any one of claims 9 to 19 wherein the subject is a human.